Cytokine dysregulation in chronic kidney disease: How can we treat it?

94Citations
Citations of this article
100Readers
Mendeley users who have this article in their library.
Get full text

Abstract

As the kidney is the major site for elimination of many cytokines, the delicate equilibrium of pro-inflammatory cytokines and their inhibitors is clearly dysregulated in chronic kidney disease (CKD) patients. The consequences of the altered immune response in uremia lead to a state of persistent inflammation which is highly prevalent among CKD patients and is linked to complications such as the development of protein-energy wasting and atherosclerotic vascular disease. The present review aims at reviewing this complex orchestration of uremic cytokines beyond the well-studied interleukin-6 and tumor necrosis factor-α. Finally, we update our current understanding on anti-inflammatory treatment strategies in CKD patients, including nutritional and lifestyle measurements, pharmacological intervention and specific anticytokine strategies targeting the dialytic procedure. Copyright © 2008 S. Karger AG.

Cite

CITATION STYLE

APA

Carrero, J. J., Yilmaz, M. I., Lindholm, B., & Stenvinkel, P. (2008, May). Cytokine dysregulation in chronic kidney disease: How can we treat it? Blood Purification. https://doi.org/10.1159/000126926

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free